(NASDAQ: OCS) Oculis Holding Ag's forecast annual revenue growth rate of 197.57% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.75%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10%.
Oculis Holding Ag's revenue in 2024 is $962,637.On average, 4 Wall Street analysts forecast OCS's revenue for 2024 to be $36,630,074, with the lowest OCS revenue forecast at $33,066,266, and the highest OCS revenue forecast at $40,414,325. On average, 4 Wall Street analysts forecast OCS's revenue for 2025 to be $523,071,580, with the lowest OCS revenue forecast at $36,372,892, and the highest OCS revenue forecast at $1,705,851,897.
In 2026, OCS is forecast to generate $911,159,316 in revenue, with the lowest revenue forecast at $687,410,919 and the highest revenue forecast at $1,109,924,312.